Pharmaceutical composition of 10-hydroxycamptothecin and biochanin A and application of pharmaceutical composition

A technology of chickpein and hydroxycamptothecin, which is applied in drug combinations, medical preparations containing active ingredients, antineoplastic drugs, etc., can solve the problem of poor solubility of chemotherapy drugs, single action target, and easy drug resistance and other problems, to achieve significant synergistic effects, reduce dosage, and improve curative effect

Pending Publication Date: 2021-12-28
DALIAN UNIV OF TECH PANJIN INST OF IND TECH
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the methods for treating cancer mainly include surgery, radiotherapy and chemotherapy, among which chemotherapy is the most commonly used. However, most chemotherapy drugs have poor solubility, strong side effects, single target, and easy drug resistance, which limits their clinical application.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition of 10-hydroxycamptothecin and biochanin A and application of pharmaceutical composition
  • Pharmaceutical composition of 10-hydroxycamptothecin and biochanin A and application of pharmaceutical composition
  • Pharmaceutical composition of 10-hydroxycamptothecin and biochanin A and application of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] This embodiment provides a pharmaceutical composition of 10-hydroxycamptothecin and biochanin A, the specific steps are as follows:

[0031] (1) MTT detects the effect of 10-hydroxycamptothecin and biochanin A single drug on the proliferation of breast cancer cell MCF7: MCF-7 cells are contained in a volume ratio of 10% fetal bovine serum, 100kU / L penicillin, 100mg / L L streptomycin in DMEM high glucose medium, 37°C, 5% CO 2 cultivated under conditions. The cells were trypsinized and counted with a hemocytometer. Inoculate in a 96-well cell culture plate at a volume of 100 μL per well (cell inoculation volume is 8000-10000 per well, select according to cell size and growth rate), 5% CO 2 After 24 hours of cultivation in a 37°C incubator, different concentration gradients of 10-hydroxycamptothecin and biochanin A were added, and 5% CO 2 , Incubate in a 37°C incubator for 48 hours. Discard the medium, wash once with PBS, and then add 100 μL of serum-free medium contain...

Embodiment 2

[0034] This embodiment provides a pharmaceutical composition of 10-hydroxycamptothecin and biochanin A, the specific steps are as follows:

[0035] (1) MTT detection of the effect of 10-hydroxycamptothecin and biochanin A single drug on the proliferation of gastric cancer cell BGC-823: BGC-823 cells were treated with 10% fetal bovine serum, 100kU / L penicillin, 100mg / L chain Mycin DMEM high glucose medium, 37°C, 5% CO 2 cultivated under conditions. The cells were trypsinized and counted with a hemocytometer. Inoculate in a 96-well cell culture plate at a volume of 100 μL per well (cell inoculation volume is 8000-10000 per well, select according to cell size and growth rate), 5% CO 2 After 24 hours of cultivation in a 37°C incubator, different concentration gradients of 10-hydroxycamptothecin and biochanin A were added, and 5% CO 2 , Incubate in a 37°C incubator for 48 hours. Discard the medium, wash once with PBS, and then add 100 μL of serum-free medium containing 0.5 mg / m...

Embodiment 3

[0038] This embodiment provides a pharmaceutical composition of 10-hydroxycamptothecin and biochanin A, the specific steps are as follows:

[0039] (1) MTT detection of 10-hydroxycamptothecin and biochanin A monotherapy on the proliferation of liver cancer cells HepG2: HepG2 cells in DMEM containing 10% fetal bovine serum, 100kU / L penicillin, 100mg / L streptomycin In high glucose medium, 37°C, 5% CO 2 cultivated under conditions. The cells were trypsinized and counted with a hemocytometer. Inoculate in a 96-well cell culture plate at a volume of 100 μL per well (cell inoculation volume is 8000-10000 per well, select according to cell size and growth rate), 5% CO 2 After 24 hours of cultivation in a 37°C incubator, different concentration gradients of 10-hydroxycamptothecin and biochanin A were added, and 5% CO 2 , Incubate in a 37°C incubator for 48 hours. Discard the medium, wash once with PBS, and then add 100 μL of serum-free medium containing 0.5 mg / mL MTT to each well ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical composition of 10-hydroxycamptothecin and biochanin A and application of the pharmaceutical composition. The pharmaceutical composition is prepared from the 10-hydroxycamptothecin and the biochanin A. The pharmaceutical composition of 10-hydroxycamptothecin and biochanin A is prepared by the following method: weighing 10-hydroxycamptothecin and biochanin A, respectively dissolving the 10-hydroxycamptothecin and biochanin A in dimethyl sulfoxide or ethanol to prepare a storage solution in which the concentration of 10-hydroxycamptothecin is 50-100 mmol / L and the concentration of biochanin A is 200-600 mmol / L, and storing the storage solution at -20 DEG C to prepare the pharmaceutical composition of the 10-hydroxycamptothecin and the biochanin A. The pharmaceutical composition has a remarkable synergistic effect, the curative effect of the medicine is improved, the dosage of the medicine is reduced, and the occurrence of side effects is reduced.

Description

technical field [0001] The invention relates to pharmaceutical technology, in particular to a pharmaceutical composition of 10-hydroxycamptothecin and biochanin A and its application. Background technique [0002] With the improvement of people's living standards, the incidence of cancer is also increasing year by year, and cancer has become a major killer that threatens human health and life. Therefore, the treatment of cancer has become an urgent problem to be solved. At present, the methods for treating cancer mainly include surgery, radiotherapy and chemotherapy, among which chemotherapy is the most commonly used. However, most chemotherapy drugs have poor solubility, strong side effects, single target, and easy drug resistance, which limits their clinical application. . Therefore, how to improve the efficacy of these chemotherapeutic drugs while reducing their toxic and side effects is an urgent problem to be solved at present. To achieve this goal, the most effectiv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4745A61K31/352A61P35/00
CPCA61K31/4745A61K31/352A61P35/00A61K2300/00
Inventor 郭建丽许建强徐卫平贺高红包永明闫志刚代新英
Owner DALIAN UNIV OF TECH PANJIN INST OF IND TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap